source
- FDA approves brexu-cel CAR-T therapy for relapsed/refractory mantle cell lymphoma, highlighting safety considerationsThe U.S. Food and Drug Administration has granted approval to brexu-cel, a CAR T-cell therapy, for patients with relapsed or refractory mantle cell lymphoma (MCL). This is the first CAR T indicatio…
- Dr. Silbermann highlights trial design priorities for multiple myeloma, from supportive care to diverse enrollmentDr. Rebecca Silbermann, an associate professor at Oregon Health & Science University, outlined key considerations for designing multiple myeloma clinical trials. She stressed the importance of alig…